KM Biologics KK

LYON, France & KUMAMOTO, Japan I September 10, 2024 I Osivax , a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, and KM Biologics Co., Ltd., a leading vaccine manufacturer in Japan, today announced a license option agreement granting KM Biologics an exclusive license option to develop, manufacture and commercialize Osivax’s broad-spectrum “universal” influenza vaccine candidates for the Japanese market. Osivax will receive an upfront payment for the execution of the license option agreement and, upon KM Biologics exercising the option, Osivax will be entitled to an additional upfront payment, payments upon achievement of several development and regulatory milestones, and tiered royalties per candidate. Financial details of the license option agreement have not been disclosed. “We highly value the opportunity to collaborate with KM Biologics, an experienced and established influenza vaccine developer and manufacturer in Japan. This presents an exciting opportunity for us to expand the reach of our broad-spectrum ‘universal’ influenza vaccine candidates to a country that is at the forefront of seasonal and pandemic flu prevention ,” said Alexandre Le Vert, CEO and Co-Founder of Osivax . “The license option agreement underscores the potential of our oligoDOM™technology to generate T-Cell vaccines capable of providing universal protection against current and future influenza strains on a global scale.” “We are impressed with the innovative potential of Osivax’s broad-spectrum ‘universal’ influenza vaccine candidates and oligoDOM™ technology ,” commented Toshiaki Nagasato, President and Representative Director of KM Biologics . “ This license option agreement opens the possibility for us to utilize KM Biologics’ capabilities, partnerships, and extensive market knowledge to bring Osivax’s novel influenza vaccines to Japan. The opportunity of this new approach to meeting the diverse needs in the influenza vaccine market will further improve vaccination rates and better control influenza disease burden, contributing towards the enhancement of the public health. ” About Osivax Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM™, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum “universal” influenza vaccine candidate, OVX836, which is currently in Phase 2 clinical trials with over 1,200 volunteers tested and encouraging efficacy proof of concept data. Osivax’s ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of Covid-19 in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide. For further information: https://osivax.com/ About KM Biologics KM Biologics is a pivotal member of the Meiji Group’s pharmaceutical segment. The company specializes in research, development, manufacturing, and supply of human vaccines and blood plasma products, as well as in newborn screening, and has been committed to enhancing the public health over 78 years history including its predecessor. The company has a proven track record of delivering a variety of high-quality vaccines and is a top manufacturer of the seasonal influenza vaccine in Japan. The company has been prepared and committed to, in the event of an influenza pandemic, supply vaccines to 57 million people. For more information, visit https://www.kmbiologics.com/en/ . SOURCE: Osivax

DUBLIN, Nov. 10, 2023 /PRNewswire/ -- The "Global Hepatitis B Virus (HBV) Vaccine Market (by End User, Composition, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering. The global hepatitis B virus (HBV) vaccine market is on a growth trajectory, expected to reach a market value of US$2.47 billion by 2023, with a robust Compound Annual Growth Rate (CAGR) of 5.33% during the projected period. Hepatitis B virus (HBV) is a liver-infecting virus transmitted through various means, including contact with infected blood or bodily fluids, sexual contact, sharing needles, or exposure in healthcare settings. Perinatal transmission from infected mothers to newborns is also a significant concern. HBV Vaccine: Key to Eradicating Hepatitis B The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030. Since the approval of the first HBV vaccine in 1981, significant advancements have occurred in the development of HBV vaccines. Vaccine recommendations have evolved over time, now advocating for universal HBV immunization for all individuals under the age of 60. Segmentation The global HBV vaccine market is segmented by end-user into Adult and Pediatric categories. The Adult HBV vaccine segment further divides into mono vaccine and combination vaccine subsegments. Combination vaccines are expected to experience the fastest growth during the forecast period, offering protection against multiple causal agents and reducing individual vaccine packaging costs. For instance, the Twinrix combination vaccine provides protection against both hepatitis B and hepatitis A. Geographic Insights Geographically, the global HBV vaccine market is divided into five regions: The US, China, European Union, Japan, and the Rest of the World (ROW). The United States leads the global market due to a high demand for the HBV vaccine, driven by ongoing HBV infection threats. Factors such as increasing HBV prevalence, government initiatives promoting vaccination, technological advancements in vaccine production, and rising healthcare expenditure are expected to sustain market growth. The European Union and the UK are poised for significant expansion, driven by improved healthcare infrastructure, active government efforts to combat HBV, and established hospital reimbursement systems. Ongoing technological advancements, increased accessibility, and rising disposable income will further boost HBV vaccination in the European region. Drivers: Rising HBV Cases Among Infants The growing incidence of HBV infection among infants is fueling the demand for HBV vaccines. Perinatal transmission of HBV poses a substantial public health challenge, leading to chronic HBV infection in infants. Chronic HBV infection can result in severe health complications, including liver cirrhosis and liver cancer. To prevent perinatal transmission, the WHO recommends testing all pregnant women for HBV infection and vaccinating infants of HBV-positive mothers soon after birth. The increasing prevalence of HBV among infants is driving greater demand for HBV vaccines as parents seek to protect their children from the virus. Challenge: Inequitable Access to Vaccines Inequitable access to vaccines remains a critical issue, particularly in impoverished areas where awareness and initiatives have faced barriers. Limited access to vaccines may be attributed to challenges such as insufficient storage facilities, lack of government support in remote regions, low literacy rates, limited health knowledge, and financial constraints. Furthermore, the unequal development and distribution of HBV vaccines and antibodies in underserved areas hinder market growth. Trend: AI Revolutionizes Vaccine and Drug Design Recent advancements in biochemistry, structural biology, immunology, microbiology, genomics, and data science have opened doors for innovation. Bioinformatics, harnessing computer techniques for biological sciences, has led to immunoinformatics, which leverages artificial intelligence and machine learning to predict complex immune system activities, such as B cell and T cell epitope prediction. The integration of AI in vaccine and drug design is poised to accelerate vaccine development, enhance efficacy, and drive the HBV vaccine market's growth. COVID-19 Impact The COVID-19 pandemic significantly impacted the HBV vaccine market by disrupting vaccine production and supply chains. Shortages of raw materials and transportation disruptions led to vaccine shortages in some regions. Additionally, pandemic-related funding shifts affected vaccination programs, including HBV initiatives. However, post-COVID prospects for the HBV vaccine market are promising. The COVAX Facility, led by WHO, has worked to ensure access to essential vaccines, including HBV vaccines. More than 2 billion doses of HBV vaccines have been secured and delivered globally through this initiative, supporting HBV vaccine production in the post-COVID era. Analysis of Key Players The global HBV vaccine market exhibits moderate concentration with growing acquisitions, collaborations, and product launches. Key players in the market include Merck & Co., Inc., GlaxoSmithKline, Sanofi, VBI Vaccines Inc., Shenzhen Kangtai Biological Products Co., Ltd., Dynavax Technologies Corporation, Meiji Group (KM Biologics), LG Chem Ltd., Cyrus Poonawalla Group (Serum Institute of India Pvt.), and Indian Immunologicals Limited. Top Impacting Factors Growth Drivers Increasing Geriatric Population Increasing Healthcare Expenditure Growing Instances of HBV Among Infants Increase in Liver Cancer and Cirrhosis Deaths due to HBV Challenges High Cost of Vaccine Development Inequitable Access to Vaccines Trends Use of AI in Vaccine and Drug Design Technological Advancements in Vaccine Administration Favorable Government Initiatives and Policies For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

New York, June 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Dengue Vaccine Market 2021-2025" - Our report on the dengue vaccine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rapid growth in disease prevalence and ineffective dengue control measures. In addition, rapid growth in disease prevalence is anticipated to boost the growth of the market as well.The dengue vaccine market analysis includes the end-user segment and geographic landscape.The dengue vaccine market is segmented as below:By End-user• Government institutions• Hospitals• NGOsBy Geographical Landscape• North America• Asia• Europe• ROWThis study identifies the initiatives for dengue vaccine research and dengue immunization programs as one of the prime reasons driving the dengue vaccine market growth during the next few years.The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on dengue vaccine market covers the following areas:• Dengue vaccine market sizing• Dengue vaccine market forecast• Dengue vaccine market industry analysisThis robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading dengue vaccine market vendors that include BioNet-Asia Co. Ltd., Chula VRC, Codagenix Inc., GeneOne Life Science Inc., Imutex Ltd., KM Biologics Co. Ltd., Medigen Biotechnology Corp., Najít Technologies Inc., Sanofi SA, and Emergex Vaccines Holding Ltd. Also, the dengue vaccine market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.Read the full report: ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________